It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alzheimer’s disease (AD) represents the most common form of dementia in the elderly with no available disease modifying treatments. Altered gut microbial composition has been widely acknowledged as a common feature of AD, which potentially contributes to progression or onset of AD. To assess the hypothesis that Candida rugosa lipase (CRL), which has been shown to enhance gut microbiome and metabolite composition, can rebalance the gut microbiome composition and reduce AD pathology, the treatment effects in APPswe/PS1de9 (APP/PS1) mice were investigated. The analysis revealed an increased abundance of Acetatifactor and Clostridiales vadin BB60 genera in the gut; increased lipid hydrolysis in the gut lumen, normalization of peripheral unsaturated fatty acids, and reduction of neuroinflammation and memory deficits post treatment. Finally, we demonstrated that the evoked benefits on memory could be transferred via fecal matter transplant (FMT) into antibiotic-induced microbiome-depleted (AIMD) wildtype mice, ameliorating their memory deficits. The findings herein contributed to improve our understanding of the role of the gut microbiome in AD’s complex networks and suggested that targeted modification of the gut could contribute to amelioration of AD neuropathology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Roskamp Institute, Sarasota, USA (GRID:grid.417518.e) (ISNI:0000 0004 0430 2305); Open University, Milton-Keynes, UK (GRID:grid.10837.3d) (ISNI:0000 0000 9606 9301)
2 Roskamp Institute, Sarasota, USA (GRID:grid.417518.e) (ISNI:0000 0004 0430 2305)
3 University of Minnesota, Division of Surgical Outcomes and Precision Medicine Research, Department of Surgery, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
4 Roskamp Institute, Sarasota, USA (GRID:grid.417518.e) (ISNI:0000 0004 0430 2305); Open University, Milton-Keynes, UK (GRID:grid.10837.3d) (ISNI:0000 0000 9606 9301); James A. Haley Veterans’ Hospital, Tampa, USA (GRID:grid.281075.9) (ISNI:0000 0001 0624 9286)